NCT02929264View on ClinicalTrials.gov

An fMRI Study in Healthy Volunteers to Investigate the Effects of ABX-1431 on Experimental Hyperalgesia and Its Neural Correlates

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions

Pain

Interventions

DRUG

ABX-1431

Capsules, 40 mg, single dose

DRUG

Placebo

Capsules, single dose

Trial Locations (1)

OX3 9DU

University of Oxford, Oxford

Sponsors

Lead Sponsor

Abide Therapeutics

All Listed Sponsors

collaborator

University of Oxford

OTHER

lead

Abide Therapeutics

INDUSTRY